HRA Pharma

HRA Pharma, founded in 1996 and headquartered in Paris, is a leading company in the fields of women's health and endocrine rare diseases, with sales and marketing subsidiaries across Europe. After developing the first emergency contraceptive based on levonorgestrel in 1999, the company became a leader in emergency contraception in Europe, with products now sold in over 50 countries worldwide. HRA Pharma has reinforced its pioneering role in women's health and endocrinology by launching a new generation product, ellaOne (an emergency contraceptive based on ulipristal acetate), which is now available in more than 80 countries globally.